Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-01-30
2007-01-30
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
Reexamination Certificate
active
10916141
ABSTRACT:
The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
REFERENCES:
patent: 6207642 (2001-03-01), Wiley
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 2002/0004041 (2002-01-01), Albert et al.
patent: 2002/0042368 (2002-04-01), Fanslow et al.
patent: 2002/0110853 (2002-08-01), Wiley
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0211993 (2003-11-01), Jakubowski et al.
patent: 2003/0216546 (2003-11-01), Tykocinski
patent: 2004/0014176 (2004-01-01), Ashkenzai et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033225 (2004-02-01), Browning et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 03/08311 (2003-10-01), None
Boucraut et al. Anti-TWEAK monoclonal antibodies reduce CNS immune cell infiltration and severity of experimental autoimmune encephalomyelitis. Autoimmunity: Mechanisms and novel Treatments, Myconos (Greece). Oct. 8-13, 2003, Abstract No. 64.
Kornek et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. Jul. 2000;157(1):267-76.
Desplat-Jego et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol. Dec. 2002;133(1-2):116-23.
Ward et al., “Blocking of Adhesion Moleculesin vivoas anti-inflammatory therapy”, Ther. Immuonol., vol. 1(3), pp. 165-171 (1994).
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox”, The Protein Folding Problem, Chapter 14, pp. 435-508 (1994).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”, Immunology, vol. 7, pp. 632-638 (1995).
Krenger and Farrara, “Graft-versus-Host Disease and the Th1/Th2 Paradigm”, Immunol. Res., vol. 15, pp. 50-73 (1996).
Chapter Fifteen, “Immunity to Microbes”, pp. 302-314 inCellular and Molecular Immunology, Abbas AK et al. (eds). Philadelphia: WB Saunders Co. (1991).
Chapter One, “General Properties of Immune Responses”, Introduction to Immunology, pp. 4-12 inCellular and Molecular Immunology, Abbas AK et al. (eds). Philadelphia: WB Saunders Co. (1991).
Toogood et al., “The Immune Response Following Small Bowel Transplantation”, Transplantation, vol. 62(6), pp. 851-855 (1996).
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”, The Journal of Immunology, col. 150(2), pp. 361-366 (1993).
Williamson et al., “IL-12 Is a Central Mediator of Acute Graft-Versus-Host Disease in Mice”, J. Immunol., pp. 689-699 (1996).
Chaplin and Fu, “Current Opinion in Immunology”, vol. 10, pp. 288-297 (1998).
Grewal and Flavell, “The CD40 Ligand”, Immunolo. Res., vol. 16, pp. 59-70 (1997).
Mackay and Browning, “Turning off follicular dendritic cells”, Nature, vol. 395, pp. 26-27 (1998).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1”, J. Exp. Med., vol. 188, pp. 297-304 (1998).
Lynch et al., “Tweak Induces Proliferation in Endothelial Cells and Substitutes For EGF and Hydrocortisone in Culture”, Interferon Cytokine Res., vol. 18, A-46 (1998).
Marsters et al., “Identification of a ligand for the death-domain-containing receptor Apo3”, Current Biology, vol. 8, pp. 525-528 (1998).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”, Science, vol. 281, pp. 1305-1308 (1998).
Lenchow et al., “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse”, J. Exp. Med., vol. 181, pp. 1145-1155 (1995).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”, J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”, Immunol. Rev., vol. 153, pp. 85-106 (1996).
Mohan et al., “Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis1”, J. Immunol., vol. 154, pp. 1470-1480 (1995).
Kalled et al., “Anti-CD40 Ligand Antibody Treatment of SNF1Mice with Established Nephritis: Preservation of Kidney Function”, J. Immunol., vol. 160, pp. 2158-2165 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein eptiopes in Chagas' patients' sera”, Parasitol. Res., vol. 84, pp. 196-799 (1998).
Tibets et al., “Cardiac Antigen-Specific Autoantibody Production is Associated with Cardiomyopathy inTrypansomacruzi-Infected Mice1”, J. Immunolo., vol. 152, pp. 1493-1499 (1994).
Kirk et al., “CTLA4-Ig and anti CD40 ligand prevent renal allograft rejection in primates”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 8789-8794 (1997).
Nagata (1997) “Apoptosis by Death Factor” Cell 88:355-365.
Kaplan et al. (1998) J. of Investigative Medicine, vol. 46:287A.
Meighan-Mantha et al. “The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration” J. Biol. Chem., Nov. 1999; 274: 33166-33176.
Cassiano et al. “Molecular Cloning of a Novel Receptor for TWEAK” Scand. J. Immunol. 51 (Supp. 1) 1-111.
Lynch et al. “TWEAK induces angiogenesis and proliferation of endothelial cells.” J Biol Chem. Mar. 26, 1999;274(13):8455-9.
Chicheportiche et al. “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies.” Biochem Biophys Res Commun. Dec. 9, 2000;279(1):162-5.
Chicheportiche et al. “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.” Arthritis Res. 2002;4(2):126-33. Epub Nov. 9, 2001.
Jakubowski, (2000), Scand. J. Immunol., 51:Sup. 1:62.
Jakubowski, (2002), J. Cell Science, “Dual Role for TWEAK in angiofenic regulation” 115:267-274.
Browning et al, “Characterization of surface lymphotoxin forms” J. Immunol, 154:33-46 (1995).
Wiley (1995) “Identification and Characterization of a New Member of the TNF Family that induces Apoptosis” Immunity, 3:673.
Y. Chicheportiche et al., “TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis,”J. of Biological Chemistry, 272(51): 32401-32410 (1997).
Ruuls et al., “The Length of Treatment Determines Whether IFN-β Prevents or Aggravates Experimental Autoimmune Encephalomyelitis in Lewis Rats”,The Journal of Immunology, vol. 157, pp. 5721-5731 (1996).
Lawrence Steinman, “Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year”The Journal of Experimental Medicine, vol. 197, No. 9, pp. 1065-1071 (2003).
Lawrence Steinman and Scott S. Zamvil, “Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis”TRENDS in Immunology, vol. 26, N
Biogen Idec MA Inc.
Haddad Maher M.
LandOfFree
Antagonists of tweak and of tweak receptor and their use to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of tweak and of tweak receptor and their use to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of tweak and of tweak receptor and their use to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732662